文献速递胃肠外科围术期管理与 ERAS

司美格鲁肽与替尔泊肽兴起后减重手术利用率的演变

Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
PubMed 文献 · Surg Endosc · 2026-07-17

基于Epic Cosmos全国数据库2018至2025年首次袖状胃切除或胃旁路术患者数据,减重手术利用率在2022年第四季度达峰后至2025年第四季度下降39%。术前使用GLP-1受体激动剂的比例从2018年第四季度0.2%升至2025年第四季度35.3%,且用药人群与直接手术人群在种族、保险类型和合并症上存在差异。

要点

  • 减重手术量2022年第四季度达峰后下降39%,术前GLP-1RA使用显著增加。
  • 术前GLP-1RA使用者多为年长、白人、私人保险、伴2型糖尿病等代谢病者。
  • 校正患者特征和年份后,医院间术前GLP-1RA使用差异达15倍,提示中心非临床因素影响大。

核心结论

  • 在Epic Cosmos数据库中,2022至2025年减重手术利用率下降,接受减重手术者术前GLP-1RA使用日益增加。
  • 术前GLP-1RA使用者多为年长、白人、私人保险、伴糖尿病及其他体重相关合并症者,直接手术者多为西班牙裔、黑人及公共保险或无保险者。
  • 术前GLP-1RA使用亦受中心特异性非临床因素驱动。

研究设计与样本

  • 回顾性数据库研究,查询Epic全国Cosmos数据库2018至2025年接受首次袖状胃切除或胃旁路术的患者。
  • 采用卡方检验和Wilcoxon秩和检验比较患者特征,改良Poisson回归识别与术前GLP-1RA使用独立相关的因素。
  • 采用多水平模型考察医院和州层面术前GLP-1RA使用的差异。

主要发现

  • 减重手术利用率在2018年第三季度后上升,2022年第四季度达峰,随后至2025年第四季度下降39%。
  • 西班牙裔减重手术患者比例从2018年第四季度8.1%升至2025年第四季度16.8%(p < 0.001)。
  • 术前接受GLP-1RA的患者比例从2018年第四季度0.2%升至2025年第四季度35.3%(p < 0.001)。
  • 与术前GLP-1RA使用相关的因素包括年份、私人保险、白人种族、2型糖尿病(RR 2.94 [2.88-3.00])、年长、睡眠呼吸暂停及代谢功能障碍相关脂肪性肝病。
  • 与直接手术相关的因素包括西班牙裔、黑人种族及公共保险或无保险。

临床怎么用

  • 普通外科医生在评估减重手术候选人时应常规询问GLP-1RA使用史,并将其纳入术前优化与手术时机决策。
  • 应关注不同种族、保险类型患者间术前用药与直接手术路径的差异,警惕诊疗可及性不均。
  • 医院层面术前GLP-1RA使用差异显著,提示需建立标准化术前用药管理流程以减少非临床因素影响。

局限性

  • 本研究为数据库回顾性分析,可能存在编码偏倚和未测量混杂因素。
  • GLP-1RA使用依据配药记录判定,可能低估实际用药或无法反映依从性。
  • 研究未报告减重手术利用率下降与GLP-1RA使用之间的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Semaglutide and tirzepatide have transformed obesity treatment, but recent changes to bariatric surgery utilization are not well understood. METHODS: Epic's nationwide Cosmos database was queried for patients who underwent primary sleeve gastrectomy or gastric bypass between 2018 and 2025. Patient characteristics including preoperative semaglutide or tirzepatide dispense history were compared using chi-squared and Wilcoxon rank sum tests. Modified Poisson regression was used to identify factors independently associated with pre-surgery GLP-1RA use. Multilevel models were used to examine hospital- and state-level variation in pre-surgery GLP-1RA use. RESULTS: Bariatric surgery utilization increased after Q3 2018, peaked in Q4 2022, and subsequently decreased 39% through Q4 2025. Between Q4 2018 and Q4 2025, the proportion of Hispanic bariatric surgery patients increased (8.1% vs. 16.8%, p < 0.001), and the proportion of patients who received pre-surgery GLP-1RA increased (0.2% vs. 35.3%, p < 0.001). Factors associated with receiving pre-surgery GLP-1RA were year, private insurance, White race, type 2 diabetes (RR 2.94 [2.88-3.00]), older age, sleep apnea, and metabolic dysfunction-associated steatotic liver disease. Factors associated with receiving surgery upfront were Hispanic ethnicity, Black race, and public or no insurance. After adjusting for patient characteristics and year, there was a 15-fold difference in pre-surgery GLP-1RA use between the highest and lowest hospitals (RR 0.19-2.88). CONCLUSIONS: In the Epic Cosmos database, bariatric surgery utilization decreased from 2022 to 2025, and those who underwent bariatric surgery increasingly received GLP-1RA before surgery. Patients who received pre-surgery GLP-1RA were older, White, privately insured, with diabetes and other weight-related comorbidities, while patients who received surgery upfront were Hispanic, Black, and publicly insured. Pre-surgery GLP-1RA use was also driven by center-specific non-clinical factors.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Kozato A, Patel SS, Orandi BJ, et al. Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide. Surg Endosc. 2026. PMID: 42467193. doi:10.1007/s00464-026-13147-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。